Cited by 143Marine Sponges and Natural ProductsMicrobial Natural Products and BiosynthesisSynthesis and Biological Activity

Clinical status of anti-cancer agents derived from marine sources

Singh, Ram, Sharma, Mukul, Joshi, Penny, Rawat, Diwan·2008·Anti-Cancer Agents in Medicinal Chemistry

Abstract

The chemical, biological and ecological diversity of the marine ecosystem has contributed immensely in the discovery of extremely potent compounds that have shown potent activities in antitumor, analgesia, antiinflammatory, immunomodulation, allergy, anti-viral etc. The compounds of marine origin are diverse in structural class from simple linear peptides to complex macrocyclic polyethers. The recent advances in the sophisticated instruments for the isolation and characterization of marine natural products and development of high-throughput screening, have substantially increased the rate of discovery of various compounds of biomedical application. Didemnin was the first marine peptide that entered in human clinical trials in US for the treatment of cancer and other compounds such as dolastatin-10, soblidotin, didemnin B, ecteinascidin 743, girolline, aplidine, cryptophycins (also arenastatin A), bryostatin 1, ILX 651, kahalalide F, E7389, discodermolide, ES-285 (spisulosine), HTI-286 (hemiasterlin derivative), squalamine, KRN-7000, vitilevuamide, Laulimalide, Curacin A, diazonamide, peloruside A, eleutherobin, sarcodictyin, thiocoraline, salicylihalimides A, ascididemnin, CGX-1160, CGX-1007dictyodendrins, GTS-21 (aka DMBX), manoalide, IPL-576,092 (aka HMR-4011A) have entered in the clinical trials. This article summarize clinical status and synthetic advances of some of these compounds. Keywords: Dolastatin-10, Ecteinascidin 743, Girolline, Bryostatin 1, Kahalalide F, Discodermolide, Squalamine, KRN-7000, Laulimalide, Thiocoraline

Integrity signals

Registry

Crossref · 10.2174/187152008785133074

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neovastat stops the binding of VEGF to its receptor.

    “On the other hand, neovastat stops the binding of VEGF to its receptor [227,229].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [227]

  • Aplidine displays anti-proliferative activity and is currently in phase I-II trials.

    “Aplidine displays promising anti-proliferative activity (currently in phase I–II trials) via characterized delay of neuromuscular toxicity and promising anti-proliferative activity (Figure 8) [227].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [227]

Cited by

Sorted by citations

Authors
Singh, R., Sharma, M., Joshi, P., & Rawat, D.
Affiliations
University of Delhi (IN)
Corresponding author
Rawat, Diwan
Venue
Anti-Cancer Agents in Medicinal Chemistry
Published
2008-08-01
Volume
8
Issue
6
Pages
603-617
ISSN
  • 1568-0118 (ISSN-L)
  • 1871-5206
OpenAlex
W4234505122
Cited by
143
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 12 · 2020: 8 · 2019: 9 · 2018: 5 · 2017: 8 · 2016: 4 · 2015: 5 · 2014: 8 · 2013: 14 · 2012: 8
FWCI
11.21
Type
journal article
Language
en
Open access
closed
Locations
  • Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
  • Health Sciences › Medicine › Pharmacology › Microbial Natural Products and Biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Synthesis and Biological Activity
Keywords
marine natural products, anticancer agents, clinical trials, marine peptides, dolastatin 10, trabectedin, bryostatin 1, kahalalide F, discodermolide, squalamine, laulimalide, synthetic analogues
MeSH terms
Animals, Antineoplastic Agents, Bacteria, Biological Products, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Invertebrates, Marine Biology, Models, Biological, Neoplasms, Oceans and Seas

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review